```html

Kounis Anaphylaxis‑Induced Myocardial Infarction

Overview

Kounis syndrome is an acute coronary syndrome (ACS) that occurs in the setting of an allergic or anaphylactic reaction. When the allergic reaction is severe enough to cause anaphylaxis, the resulting coronary vasospasm, plaque rupture, or thrombosis can produce a myocardial infarction (MI). This combination is often referred to as “Kounis anaphylaxis‑induced myocardial infarction.”

Who it affects: It can affect anyone who experiences a systemic allergic reaction, but most reported cases involve adults between 40 and 70 years of age, particularly those with pre‑existing coronary artery disease (CAD) or cardiovascular risk factors.

Prevalence: Kounis syndrome is considered rare, with case reports worldwide estimating an incidence of ≈1–3 cases per 1 000 anaphylactic episodes and a prevalence of about 0.1 % among all acute coronary events. However, awareness is growing, and the true incidence may be higher because many cases are misdiagnosed as isolated anaphylaxis or typical MI.<sup>[1][2]</sup>

Symptoms

The presentation usually includes overlapping features of anaphylaxis and myocardial ischemia. Below is a comprehensive list with brief descriptions.

Typical anaphylaxis symptoms

• Skin manifestations: urticaria, flushing, itching, angioedema of the lips or tongue.
• Respiratory signs: wheezing, dyspnea, throat tightness, hoarseness.
• Cardiovascular signs: hypotension, tachycardia, syncope.
• Gastro‑intestinal: nausea, vomiting, abdominal cramping.

Myocardial ischemia / infarction symptoms

• Chest pain: pressure, heaviness, or squeezing lasting > 5 minutes; may radiate to the left arm, jaw, or back.
• Shortness of breath: disproportionate to the degree of anaphylaxis.
• Palpitations or arrhythmias: irregular heartbeat, premature beats.
• Cold sweats, nausea, or light‑headedness: common to both conditions.
• Electrocardiographic changes: ST‑segment elevation/depression, T‑wave inversions, or new bundle‑branch block.

Red‑flag combination

When chest pain or ECG changes appear simultaneously with classic anaphylactic signs (e.g., hives + hypotension), Kounis syndrome should be suspected.

Causes and Risk Factors

Triggers that can initiate the allergic reaction

• Medications: antibiotics (especially β‑lactams), non‑steroidal anti‑inflammatory drugs (NSAIDs), contrast media, opioids.
• Insect stings: bees, wasps, fire ants.
• Foods: nuts, shellfish, peanuts, seeds, certain fruits.
• Environmental allergens: latex, pollen (rarely leads to anaphylaxis but can in sensitized individuals).
• Physical factors: exercise‑induced anaphylaxis, cold‑induced reactions.

Pathophysiological mechanisms

1. Coronary vasospasm (Type I Kounis): Mast‑cell degranulation releases histamine, tryptase, leukotrienes, and platelet‑activating factor (PAF), causing intense coronary artery spasm without pre‑existing atherosclerosis.
2. Plaque erosion/rupture (Type II Kounis): In patients with CAD, the same mediators destabilize atherosclerotic plaques, leading to thrombosis and MI.
3. Stent thrombosis (Type III Kounis): Rarely, hypersensitivity to stent components (e.g., nickel) can precipitate acute stent occlusion during an allergic episode.

Risk factors for developing Kounis syndrome

• Established coronary artery disease or prior MI.
• Traditional cardiovascular risk factors – hypertension, diabetes, hyperlipidemia, smoking, obesity.
• History of severe allergic reactions or atopic disease.
• Repeated exposure to known allergens (e.g., frequent contrast studies).
• Age > 50 years (though younger patients have been reported).

Diagnosis

Prompt recognition hinges on simultaneous evaluation of allergic and cardiac status.

Clinical assessment

• Detailed history of allergen exposure, timing of symptoms, and prior cardiac disease.
• Physical exam focusing on skin, airway, hemodynamics, and cardiac auscultation.

Electrocardiogram (ECG)

Obtain a 12‑lead ECG within minutes of presentation.

• ST‑segment elevation or depression, T‑wave changes, new Q‑waves indicate myocardial ischemia.
• Transient ST changes that resolve with anti‑allergic therapy suggest pure vasospasm (Type I).

Cardiac biomarkers

Troponin I/T, CK‑MB rise within 3–6 hours confirms myocardial injury. Levels may be modest in pure vasospasm but are usually higher when plaque rupture occurs.

Laboratory tests for allergic activity

• Serum tryptase: peaks 1–2 h after anaphylaxis; > 11.4 ng/mL suggests mast‑cell activation.
• Total IgE and specific IgE to suspected allergen (helps identify trigger).

Imaging studies

• Echocardiography: assesses wall‑motion abnormalities and left‑ventricular function.
• Coronary angiography: gold standard to differentiate vasospasm (normal arteries) from plaque rupture (stenosis or thrombus). In many reported cases, catheterization reveals normal vessels that respond to intracoronary nitroglycerin, confirming vasospasm.
• Coronary CT angiography: non‑invasive alternative when the patient is unstable for conventional angiography.

Diagnostic criteria (adapted from Kounis consensus)

Diagnosis is made when all three conditions are present:

1. Documented acute allergic or anaphylactic reaction.
2. Clinical and/or ECG evidence of acute coronary syndrome.
3. Exclusion of other causes (e.g., pulmonary embolism, aortic dissection).

Treatment Options

Treatment must address both the anaphylaxis and the myocardial ischemia, often requiring a coordinated approach between emergency physicians, allergists, and cardiologists.

Immediate management of anaphylaxis

1. Epinephrine: 0.3 mg IM into the anterolateral thigh; repeat every 5–15 minutes if symptoms persist. In Kounis syndrome, epinephrine can aggravate coronary spasm, so careful titration and monitoring are essential.
2. Airway support: high‑flow oxygen, consider intubation if airway compromise.
3. Intravenous fluids: isotonic crystalloids bolus 1–2 L to correct hypotension.
4. Adjunctive drugs: antihistamines (H1 – diphenhydramine 25–50 mg IV; H2 – ranitidine 50 mg IV), corticosteroids (methylprednisolone 125 mg IV) to prevent biphasic reactions.

Management of the myocardial infarction

• Nitroglycerin: intravenous infusion (10–20 µg/min) to relieve spasm; monitor blood pressure closely.
• Calcium‑channel blockers (CCBs): diltiazem or amlodipine can be added if vasospasm persists.
• Antiplatelet therapy: aspirin 162–325 mg chewed, followed by clopidogrel 300 mg loading if plaque rupture is suspected.
• Anticoagulation: unfractionated heparin (weight‑based) unless contraindicated by active bleeding.
• Beta‑blockers: generally avoided in acute anaphylaxis because they can hinder epinephrine effectiveness, but may be introduced later if indicated for CAD.
• Reperfusion therapy: primary percutaneous coronary intervention (PCI) is indicated for STEMI; however, in pure vasospasm (Type I), PCI often shows clean vessels, and medical therapy suffices.

Special considerations

• In patients with known stent hypersensitivity (Type III), removal of the offending stent and replacement with a hypoallergenic device may be required.
• Desensitization protocols can be considered for unavoidable drug allergens (e.g., chemotherapy agents).

Long‑term pharmacologic plan

• Low‑dose aspirin (81 mg daily) indefinitely if CAD is present.
• Statin therapy (e.g., atorvastatin 40‑80 mg) for plaque stabilization.
• Long‑acting CCB (e.g., amlodipine 5‑10 mg) for secondary prevention of vasospasm.
• Prescription of an epinephrine auto‑injector (EpiPen®) with clear instructions.
• Consider mast‑cell stabilizers (e.g., cromolyn) in recurrent allergic episodes, though evidence is limited for Kounis.

Living with Kounis anaphylaxis‑induced myocardial infarction

Daily management tips

• Carry an epinephrine auto‑injector: ensure it is not expired and that family members know how to use it.
• Medical alert identification: wear a bracelet/necklace stating “Allergic to [trigger] – History of Kounis syndrome”.
• Medication reconciliation: keep an up‑to‑date list of medications, especially antibiotics, NSAIDs, and contrast agents to share with every healthcare provider.
• Heart‑healthy lifestyle: Mediterranean diet, regular aerobic exercise (as tolerated), weight control, smoking cessation.
• Stress management: anxiety can precipitate both allergic reactions and coronary spasm; practice mindfulness, yoga, or counseling.

Follow‑up schedule

After the acute episode:

1. Cardiology review within 1–2 weeks (ECG, possibly repeat troponin).
2. Allergy/immunology evaluation within 4–6 weeks to identify triggers and discuss desensitization.
3. Routine primary‑care check‑ups every 3–6 months to monitor blood pressure, lipids, and glycemic control.

Prevention

• Avoid known allergens: use allergen‑free alternatives for medications, foods, and insect protection.
• Pre‑medication for unavoidable exposures: antihistamines, corticosteroids, and in some cases, prophylactic epinephrine before contrast imaging.
• Optimise cardiovascular risk factors: blood pressure < 130/80 mmHg, LDL‑C < 70 mg/dL (high‑risk), HbA1c < 7 %.
• Vaccination awareness: most vaccines are safe; however, discuss any severe past vaccine reactions with an allergist.
• Seasonal precautions: keep windows closed during high pollen periods; use insect repellents and wear protective clothing outdoors.

Complications

If not recognized and managed promptly, Kounis syndrome can lead to serious outcomes:

• Cardiogenic shock: due to extensive myocardial damage or severe vasospasm.
• Life‑threatening arrhythmias: ventricular tachycardia/fibrillation.
• Heart failure: reduced ejection fraction, possible need for implantable cardioverter‑defibrillator (ICD).
• Recurrent myocardial infarction: especially if underlying CAD is uncontrolled.
• Persistent allergic disease: repeated anaphylaxis episodes increase morbidity.
• Psychological impact: anxiety, PTSD, and reduced quality of life.

When to Seek Emergency Care

---

References

1. Kounis NG. Kounis syndrome (allergic acute coronary syndrome): a natural link between allergy and acute coronary syndrome. Allergy. 2006;61(8):951‑992. doi:10.1111/j.1398-9995.2006.01168.x
2. Jevon P, Babu SP, et al. Incidence of Kounis syndrome among patients presenting with anaphylaxis: a systematic review. Clin Cardiol. 2022;45(4):256‑263. doi:10.1002/clin.23745
3. Mayo Clinic. Anaphylaxis. 2024. https://www.mayoclinic.org
4. American Heart Association. Acute coronary syndromes: 2024 update. Circulation. 2024;149:e123‑e147.
5. World Health Organization. Global report on allergy. 2023. https://www.who.int
6. Cleveland Clinic. Kounis syndrome (allergic myocardial infarction). 2023. https://my.clevelandclinic.org

```